泌尿器がん治療薬の世界市場：2024年～2031年

レポート概要

世界の泌尿器がん治療薬の市場規模は、2023年に36億米ドルに達し、2024年～2031年の予測期間中にCAGR11.9%で成長し、2031年には86億米ドルに達すると予測されています。

泌尿器系がんは、男性および女性の泌尿器系の器官や構造、男性の生殖器系に影響を及ぼします。これらのがんはかなり一般的です。膀胱がんは、排泄のために尿を入れる小さな袋である膀胱を覆う細胞を侵します。腎臓がんは、腎臓の血液をきれいにする小さな管にできるがんです。腎盂がんは、膀胱につながる腎臓に発生するまれな病型です。精巣がんは精巣にできるがんで、男性のがん全体の1％しかありません。尿道がんは、膀胱から体外へ尿を送る管である尿道に発生します。まれで、女性よりも男性に多く発生します。

症状が出るのはがんが進行してからです。血尿（痛みを伴わない）は、膀胱がん、腎臓がん、前立腺がんの症状で、さらに進行すると骨盤痛や背部痛を伴うこともあります。前立腺がんの患者では、排尿や性機能にも変化がみられることがあります。精巣がんや陰茎がんの患者は、皮膚の変化や腫れとともに、皮膚に目に見える病変を認めます。がん患者であれば誰でも、体重減少や疲労を経験する可能性があります。

市場力学：

促進要因

泌尿器系がんの有病率の増加

泌尿器系がんの有病率の増加は、市場の成長を促進します。例えば、米国がん協会が発表した記事によると、膀胱がんは主に高齢者に発生します。このがんにかかる人の約10人中9人は55歳以上です。膀胱がんと診断される人の平均年齢は73歳です。全体として、男性が一生の間にこのがんを発症する確率は約28分の1です。女性の場合は89人に1人の確率です。

英国では、毎年平均5万2,000人以上の男性が前立腺がんと診断されており、イングランドでは、毎年4万4,000人以上の男性が前立腺がんと診断されています。イングランドでは毎年1万人以上の男性が前立腺がんで死亡しています。スコットランドでは毎年3,800人以上の男性が前立腺がんと診断され、毎年1,000人以上の男性が前立腺がんで死亡しています。ウェールズでは毎年2,800人以上の男性が前立腺がんと診断され、毎年約630人の男性が前立腺がんで死亡しています。

抑制要因

化学療法や放射線療法の治療費が高いことなどが市場を妨げると予想されます。化学療法や放射線療法に使用される薬剤は非常に高価であり、泌尿器がんに罹患しているすべての人が購入できる価格ではありません。

市場セグメンテーション

世界の泌尿器がん治療薬市場は、製品、用途、エンドユーザー、地域によって区分されます。

前立腺がんセグメントは、世界の泌尿器がん治療薬市場シェアの約56.8%を占める

予測期間中、前立腺がんセグメントが最大の市場シェアを占めると予想されます。このセグメントでは、技術の進歩がこの市場を牽引すると思われます。

前立腺がんは、膀胱の下にある男性生殖器官の腺である前立腺における細胞の制御不能な増殖です。前立腺組織の異常増殖は通常、スクリーニング検査、典型的には前立腺特異抗原（PSA）値を調べる血液検査によって発見されます。血液中のPSA値が高い人は、前立腺がんを発症するリスクが高いです。

例えば、リンパーザ（オラパリブ）は、BRCA遺伝子変異を有する転移性去勢抵抗性前立腺がん（mCRPC）の治療薬として、2023年5月に米国食品医薬品局（FDA）により承認されました。この承認により、リンパーザはザイティガ（アビラテロン）および副腎皮質ステロイドとの併用で承認された初めてのPARP阻害剤となります。前立腺がんは、肺がんに次いで米国人男性のがん死亡原因の第2位を占めています。約44人に1人が前立腺がんで死亡します。2022年の前立腺がんの新規症例数は146万7,854例です。

地域別の市場シェア

泌尿器がん治療薬の世界市場シェアは北米が約41.6%を占める

予測期間中、北米が最大の市場シェアを占めると予想されます。泌尿器系がんの罹患率の上昇と、この地域における技術の進歩が市場の推進力となっています。

例えば、米国疾病予防管理センター（Centers for Disease Control and Prevention）が発表した記事によると、入手可能な最新のデータに基づくと、米国では2022年に3万3,363人の男性が前立腺がんで死亡しています。前立腺がんの新規罹患率は、男性10万人当たり年間116.5人です。死亡率は男性10万人当たり年間19.0人でした。男性の約12.8％が生涯のある時点で前立腺がんと診断されます。

腎臓がんは、米国では男女ともに10大がんの1つです。がん全体の約4～5％を占めます。全体として、男性の腎臓がんの生涯発症リスクは43人に1人（2.3％）です。女性の生涯リスクは約73人に1人（1.4％）です。2024年8月、この無作為化能動比較試験のエビデンスに基づき、ベルズチファンは米国食品医薬品局により、ICIまたは抗血管新生療法による標準治療後の進行腎細胞がん（RCC）成人患者を対象に承認されました。HIF-2a阻害剤のこの承認は、進行腎細胞がんにおける新規治療機序を有する薬剤に対するニーズに応えるものです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 泌尿器系がんの有病率の増加
  • 抑制要因
    • 化学療法と放射線療法の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 製品別

• 錠剤
• 注射剤
• その他

第7章 用途別

• 前立腺がん
• 膀胱がん
• 腎臓がん
• 尿道がん
• その他

第8章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Johnson & Johnson Services Inc.
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Abbott
• Sanofi
• GlaxoSmithKline Plc.

第12章 付録

Report Overview

The Global Urological Cancer Drugs Market reached US$ 3.6 billion in 2023 and is expected to reach US$ 8.6 billion by 2031, growing at a CAGR of 11.9% during the forecast period 2024-2031.

Urological cancers affect the male and female urinary system's organs and structures and the male reproductive system. These cancers are fairly common. Types of urological cancers are, bladder cancer affects the cells that line the urinary bladder, a small sac containing urine for excretion. Renal cancer forms in the tiny tubes that clean the blood of the kidneys. Renal pelvic cancer is a rare form of this disease that occurs in the kidney that connects to the bladder. Testicular cancer forms in the testis and accounts for only one percent of all cancers in men. Urethral cancer occurs in the urethra, the tube that conducts urine from the bladder to the outside of the body. It is rare and occurs more often in men than in women.

Symptoms do not occur until the cancer has become more advanced. Blood in the urine (without pain) is a symptom of bladder, kidney, and prostate cancer-at later stages, pelvic and back pain can also develop. Patients with prostate cancer may also have other changes in urination and sexual function. Those with testicular or penile cancer notice a visible lesion on the skin, along with other skin changes or swelling. Any cancer patient can experience weight loss and fatigue.

Market Dynamics: Drivers

Increasing prevalence of urological cancers

The rising prevalence of urological cancers propels the market growth. For instance, according to an article published by the American Cancer Society, bladder cancer occurs mainly in older people. About 9 out of 10 people with this cancer are over the age of 55. The average age of people when they are diagnosed with bladder cancer is 73. Overall, the chance men will develop this cancer during their lifetime is about 1 in 28. For women, the chance is about 1 in 89.

In the UK, more than 52,000 men are diagnosed with prostate cancer every year on average, that is 144 men every day. More than 44,000 men are diagnosed with prostate cancer every year in England. More than 10,000 men die from prostate cancer every year in England. More than 3,800 men are diagnosed with prostate cancer every year in Scotland. More than 1,000 men die from prostate cancer every year in Scotland. More than 2,800 are diagnosed with prostate cancer every year in Wales. Around 630 men die from prostate cancer every year in Wales.

Restraints

Factors such as the high cost of chemotherapy and radiation therapy treatment are expected to hamper the market. The drugs that are used for chemotherapy and radiation therapy are very expensive and it is not affordable for all the people who are suffering from urological cancer.

Market Segment Analysis

The global urological cancer drugs market is segmented based on product, application, end-user, and region.

The segment prostate cancer accounted for approximately 56.8% of the global urological cancer drugs market share

The prostate cancer segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.

Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer.

For instance, Lynparza (olaparib) was approved by the U.S. Food and Drug Administration (FDA) in May 2023, to treat BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval makes Lynparza the first PARP inhibitor approved in combination with Zytiga (abiraterone) and a corticosteroid. Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. About 1 in 44 men will die of prostate cancer. There were 1,467,854 new cases of prostate cancer in 2022.

Market Geographical Share

North America accounted for approximately 41.6% of the global urological cancer drugs market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of urological cancers, and technological advancements in this region, help to propel the market.

For instance, according to an article published Centers for Disease Control and Prevention, based on the most recent data available, in the United States in 2022, 33,363 males died from prostate cancer. The rate of new cases of prostate cancer was 116.5 per 100,000 men per year. The death rate was 19.0 per 100,000 men per year. Approximately 12.8 percent of men will be diagnosed with prostate cancer at some point during their lifetime.

Kidney cancer is one of the 10 most common cancers in both men and women in the United States. It accounts for about 4% to 5% of all cancers. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 43 (2.3%). The lifetime risk for women is about 1 in 73 (1.4%). In August 2024, based on the evidence from this randomized, active-controlled trial, belzutifan was approved by the U.S. Food and Drug Administration for adult patients with advanced renal cell carcinoma (RCC) following standard treatment with an ICI or anti-angiogenic therapy. This approval of a HIF-2a inhibitor meets a need for drugs with novel therapeutic mechanisms in advanced renal cell carcinoma.

Market Segmentation

By Product

Tablet

Enzalutamide

Abiraterone

Injection

Goserelin

Triptorelin Pamoate

Others

By Application

Prostate Cancer

Bladder Cancer

Kidney Cancer

Urethral Cancer

Others

By End-User

Hospitals

Specialty Clinics

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global urological cancer drugs market include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Johnson & Johnson Services, Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Abbott, Sanofi, GlaxoSmithKline Plc., among others.

Key Developments

In April 2024, the U.S. Food and Drug Administration (FDA) approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer.

In January 2024, Pfizer's oral poly ADP-ribose polymerase (PARP) inhibitor TALZENNA(R) (talazoparib), in combination with XTANDI(R) (enzalutamide) was approved for prostate cancer by the European Commission (EC)

Why Purchase the Report?

To visualize the global urological cancer drugs market segmentation based on product, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global urological cancer drugs market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global urological cancer drugs market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Urological Cancers
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Chemotherapy and Radiation Therapy
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Product

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Tablet*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Injection
• 6.4. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Prostate Cancer*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bladder Cancer
• 7.4. Kidney Cancer
• 7.5. Urethral Cancer
• 7.6. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Novartis AG *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Pfizer Inc.
• 11.3. F. Hoffmann-La Roche Ltd.
• 11.4. AstraZeneca
• 11.5. Johnson & Johnson Services Inc.
• 11.6. Astellas Pharma Inc.
• 11.7. Bristol-Myers Squibb Company
• 11.8. Abbott
• 11.9. Sanofi
• 11.10. GlaxoSmithKline Plc. (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us